Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Adverse Effect of Post-Discharge Care Fragmentation on Outcomes after Readmissions after Liver Transplantation.

Kothari AN, Loy VM, Brownlee SA, Ezure Y, Schaidle-Blackburn C, Cotler SJ, di Sabato D, Kuo PC, Lu AD.

J Am Coll Surg. 2017 Jul;225(1):62-67. doi: 10.1016/j.jamcollsurg.2017.03.017. Epub 2017 Apr 9.

PMID:
28400298
2.

Perioperative support, not volume, is necessary to optimize outcomes in surgical management of necrotizing enterocolitis.

Cobb AN, Wong YM, Brownlee SA, Blanco BA, Ezure Y, Paddock HN, Kuo PC, Kothari AN.

Am J Surg. 2017 Mar;213(3):502-506. doi: 10.1016/j.amjsurg.2016.11.014. Epub 2016 Nov 9.

3.

"Take the Volume Pledge" may result in disparity in access to care.

Blanco BA, Kothari AN, Blackwell RH, Brownlee SA, Yau RM, Attisha JP, Ezure Y, Pappas S, Kuo PC, Abood GJ.

Surgery. 2017 Mar;161(3):837-845. doi: 10.1016/j.surg.2016.07.017. Epub 2016 Nov 14.

PMID:
27855970
4.

Tannins of tamarind seed husk: preparation, structural characterization, and antioxidant activities.

Sinchaiyakit P, Ezure Y, Sriprang S, Pongbangpho S, Povichit N, Suttajit M.

Nat Prod Commun. 2011 Jun;6(6):829-34.

PMID:
21815420
5.

Catalase, a specific antigen in the feces of human subjects infected with Helicobacter pylori.

Suzuki N, Wakasugi M, Nakaya S, Kokubo N, Sato M, Kajiyama H, Takahashi R, Hirata H, Ezure Y, Fukuda Y, Shimoyama T.

Clin Diagn Lab Immunol. 2002 Jul;9(4):784-8.

6.

The effects of several vasopressin receptor antagonists on normal intraocular pressure and the intraocular distribution of vasopressin receptor subtypes.

Naito A, Kurasawa T, Ohtake Y, Toyoda Y, Ezure Y, Koike K, Shigenobu K.

Biol Pharm Bull. 2002 Feb;25(2):251-5.

7.

Production and application of new monoclonal antibodies specific for a fecal Helicobacter pylori antigen.

Suzuki N, Wakasugi M, Nakaya S, Okada K, Mochida R, Sato M, Kajiyama H, Takahashi R, Hirata H, Ezure Y, Koga Y, Fukuda Y, Shimoyama T.

Clin Diagn Lab Immunol. 2002 Jan;9(1):75-8.

8.
9.

Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition.

Takahashi H, Akiba K, Noguchi T, Ohmura T, Takahashi R, Ezure Y, Ohara K, Zieske JD.

Curr Eye Res. 2000 Aug;21(2):608-15.

PMID:
11148597
10.

The therapeutic efficacy of VP-343, a selective vasopressin V2 receptor antagonist, in the experimental SIADH rat model.

Naito A, Hasegawa H, Kurasawa T, Ohtake Y, Matsukawa H, Ezure Y, Tsuriya Y, Koike K, Shigenobu K.

Biol Pharm Bull. 2000 Nov;23(11):1323-7.

PMID:
11085360
11.

Affinity chromatography for purification of two urokinases from human urine.

Takahashi R, Akiba K, Koike M, Noguchi T, Ezure Y.

J Chromatogr B Biomed Sci Appl. 2000 May 26;742(1):71-8.

PMID:
10892585
12.

Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.

Naito A, Ohtake Y, Hasegaw H, Fukaya AY, Kurasawa T, Naito K, Matsukawa H, Oguma T, Ezure Y, Tsuriya Y, Tanaka H, Koike K, Shigenobu K.

Biol Pharm Bull. 2000 Feb;23(2):182-9.

PMID:
10706381
13.

Novel vasopressin V2 receptor-selective antagonists, pyrrolo[2,1-a]quinoxaline and pyrrolo[2,1-c][1,4]benzodiazepine derivatives.

Ohtake Y, Naito A, Hasegawa H, Kawano K, Morizono D, Taniguchi M, Tanaka Y, Matsukawa H, Naito K, Oguma T, Ezure Y, Tsuriya Y.

Bioorg Med Chem. 1999 Jun;7(6):1247-54.

PMID:
10428398
14.

Manufacturing High Purity Maltose and Maltotetraose from Starch by a Novel and Efficient Procedure Named "Reducing End Modification Method".

Ezure Y, Maruo S, Kojima M, Sakai T, Yamamoto H, Tachikake N, Ogawa H, Toda M.

Biosci Biotechnol Biochem. 1997 Jan;61(11):1931-3. doi: 10.1271/bbb.61.1931.

15.

Enzymatic synthesis of 4-O-beta-D-galactopyranosyl-moranoline and 3-O-beta-D-galactopyranosyl-moranoline by using beta-galactosidase from Bacillus circulans.

Kojima M, Seto T, Kyotani Y, Ogawa H, Kitazawa S, Mori K, Maruo S, Ohgi T, Ezure Y.

Biosci Biotechnol Biochem. 1996 Apr;60(4):694-6.

16.

Effects of moranoline, 4-O-alpha-D-glucopyranosylmoranoline and their N-substituted derivatives on thermostability of cyclodextrin glycosyltransferase, glucoamylase, and beta-amylase.

Maruo S, Kyotani Y, Yamamoto H, Miyazaki K, Ogawa H, Sakai T, Kojima M, Ezure Y.

Biosci Biotechnol Biochem. 1993 Aug;57(8):1294-8.

17.

Enzymatic synthesis of high purity maltotetraose using moranoline (1-deoxynojirimycin).

Maruo S, Yamamoto H, Toda M, Tachikake N, Kojima M, Ezure Y.

Biosci Biotechnol Biochem. 1993 Mar;57(3):499-501. No abstract available.

18.

A novel and efficient method for enzymatic synthesis of high purity maltose using moranoline (1-deoxynojirimycin).

Maruo S, Yamashita H, Miyazaki K, Yamamoto H, Kyotani Y, Ogawa H, Kojima M, Ezure Y.

Biosci Biotechnol Biochem. 1992 Sep;56(9):1406-9.

19.

Synthesis and alpha-glucosidase-inhibiting activity of a new alpha-glucosidase inhibitor, 4-O-alpha-D-glucopyranosylmoranoline and its N-substituted derivatives.

Yoshikuni Y, Ezure Y, Seto T, Mori K, Watanabe M, Enomoto H.

Chem Pharm Bull (Tokyo). 1989 Jan;37(1):106-9.

PMID:
2655949
20.

Isolation of 1,5-dideoxy-1,5-imino-D-mannitol from culture broth of Streptomyces species.

Ezure Y, Ojima N, Konno K, Miyazaki K, Yamada N, Sugiyama M, Itoh M, Nakamura T.

J Antibiot (Tokyo). 1988 Aug;41(8):1142-4. No abstract available.

21.

Inhibition of intestinal alpha-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives.

Yoshikuni Y, Ezure Y, Aoyagi Y, Enomoto H.

J Pharmacobiodyn. 1988 May;11(5):356-62. Erratum in: J Pharmacobiodyn 1988 Dec;11(12):849.

PMID:
2971794
22.

OF4949, new inhibitors of aminopeptidase B. II. Elucidation of structure.

Sano S, Ikai K, Katayama K, Takesako K, Nakamura T, Obayashi A, Ezure Y, Enomoto H.

J Antibiot (Tokyo). 1986 Dec;39(12):1685-96.

23.

OF4949, new inhibitors of aminopeptidase B. I. Taxonomy, fermentation, isolation and characterization.

Sano S, Ikai K, Kuroda H, Nakamura T, Obayashi A, Ezure Y, Enomoto H.

J Antibiot (Tokyo). 1986 Dec;39(12):1674-84.

Supplemental Content

Support Center